302 related articles for article (PubMed ID: 37414763)
1. Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma.
Fang J; Singh S; Cheng C; Natarajan S; Sheppard H; Abu-Zaid A; Durbin AD; Lee HW; Wu Q; Steele J; Connelly JP; Jin H; Chen W; Fan Y; Pruett-Miller SM; Rehg JE; Koo SC; Santiago T; Emmons J; Cairo S; Wang R; Glazer ES; Murphy AJ; Chen T; Davidoff AM; Armengol C; Easton J; Chen X; Yang J
Nat Commun; 2023 Jul; 14(1):4003. PubMed ID: 37414763
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
3. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma.
Clavería-Cabello A; Herranz JM; Latasa MU; Arechederra M; Uriarte I; Pineda-Lucena A; Prosper F; Berraondo P; Alonso C; Sangro B; García Marin JJ; Martinez-Chantar ML; Ciordia S; Corrales FJ; Francalanci P; Alaggio R; Zucman-Rossi J; Indersie E; Cairo S; Domingo-Sàbat M; Zanatto L; Sancho-Bru P; Armengol C; Berasain C; Fernandez-Barrena MG; Avila MA
J Hepatol; 2023 Oct; 79(4):989-1005. PubMed ID: 37302584
[TBL] [Abstract][Full Text] [Related]
4. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma.
Fuchs J; Wenderoth M; von Schweinitz D; Haindl J; Leuschner I
Cancer; 1998 Dec; 83(11):2400-7. PubMed ID: 9840541
[TBL] [Abstract][Full Text] [Related]
5. Single-cell analysis of hepatoblastoma identifies tumor signatures that predict chemotherapy susceptibility using patient-specific tumor spheroids.
Song H; Bucher S; Rosenberg K; Tsui M; Burhan D; Hoffman D; Cho SJ; Rangaswami A; Breese M; Leung S; Ventura MVP; Sweet-Cordero EA; Huang FW; Nijagal A; Wang B
Nat Commun; 2022 Aug; 13(1):4878. PubMed ID: 36008377
[TBL] [Abstract][Full Text] [Related]
6. Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma.
Beck A; Eberherr C; Hagemann M; Cairo S; Häberle B; Vokuhl C; von Schweinitz D; Kappler R
Cancer Biol Ther; 2016 Nov; 17(11):1168-1176. PubMed ID: 27635950
[TBL] [Abstract][Full Text] [Related]
7. Teratoid hepatoblastoma with abundant cholangioblastic component in a child with full trisomy 13.
Zhou S; Ranganathan S; Venkatramani R; Gomulia E; Wang L
Pediatr Dev Pathol; 2013; 16(6):438-41. PubMed ID: 23927400
[TBL] [Abstract][Full Text] [Related]
8. Increased efficacy of CDDP in a xenograft model of hepatoblastoma using the apoptosis sensitizer ABT-737.
Lieber J; Dewerth A; Wenz J; Kirchner B; Eicher C; Warmann SW; Fuchs J; Armeanu-Ebinger S
Oncol Rep; 2013 Feb; 29(2):646-52. PubMed ID: 23229825
[TBL] [Abstract][Full Text] [Related]
9. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99].
Häberle B; Bode U; von Schweinitz D
Klin Padiatr; 2003; 215(3):159-65. PubMed ID: 12778356
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Markert HR; Easlick JL; Stewart JE; Crossman DK; Mroczek-Musulman E; Beierle EA
Cancer Gene Ther; 2022 May; 29(5):558-572. PubMed ID: 33864024
[TBL] [Abstract][Full Text] [Related]
12. PRMT1 loss sensitizes cells to PRMT5 inhibition.
Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
[TBL] [Abstract][Full Text] [Related]
13. MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma.
Woodfield SE; Shi Y; Patel RH; Chen Z; Shah AP; Srivastava RK; Whitlock RS; Ibarra AM; Larson SR; Sarabia SF; Badachhape A; Starosolski Z; Ghaghada KB; Sumazin P; Annis DA; López-Terrada D; Vasudevan SA
Sci Rep; 2021 Feb; 11(1):2967. PubMed ID: 33536467
[TBL] [Abstract][Full Text] [Related]
14. Genetic changes in hepatoblastoma.
Ding SF; Michail NE; Habib NA
J Hepatol; 1994 May; 20(5):672-5. PubMed ID: 8071546
[No Abstract] [Full Text] [Related]
15. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.
Ortega JA; Douglass EC; Feusner JH; Reynolds M; Quinn JJ; Finegold MJ; Haas JE; King DR; Liu-Mares W; Sensel MG; Krailo MD
J Clin Oncol; 2000 Jul; 18(14):2665-75. PubMed ID: 10894865
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of p27/KIP 1 gene expression in hepatoblastoma and prognostic implications with correlation before and after chemotherapy.
Brotto M; Finegold MJ
Hum Pathol; 2002 Feb; 33(2):198-205. PubMed ID: 11957145
[TBL] [Abstract][Full Text] [Related]
17. A kinome siRNA screen identifies HGS as a potential target for liver cancers with oncogenic mutations in CTNNB1.
Canal F; Anthony E; Lescure A; Del Nery E; Camonis J; Perez F; Ragazzon B; Perret C
BMC Cancer; 2015 Dec; 15():1020. PubMed ID: 26715116
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of resistance associated genes in hepatoblastoma xenografts incorporated into mice following treatment with adriamycin or cisplatin.
Bader P; Fuchs J; Wenderoth M; von Schweinitz D; Niethammer D; Beck JF
Anticancer Res; 1998; 18(4C):3127-32. PubMed ID: 9713521
[TBL] [Abstract][Full Text] [Related]
19. Loss of Apc Cooperates with Activated Oncogenes to Induce Liver Tumor Formation in Mice.
Zhang Y; Liang B; Song X; Wang H; Evert M; Zhou Y; Calvisi DF; Tang L; Chen X
Am J Pathol; 2021 May; 191(5):930-946. PubMed ID: 33545120
[TBL] [Abstract][Full Text] [Related]
20. Potential therapies for residual hepatoblastoma following incomplete ablation treatment in a nude mouse subcutaneous xenograft model based on lncRNA and mRNA expression profiles.
Wang XD; Peng JB; Zhou CY; Que Q; Li HY; He Y; Yang H
Oncol Rep; 2020 Jun; 43(6):1915-1927. PubMed ID: 32186781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
